Treatment of renal fibrosis
AssigneesHadasit, State of Israel, Collgard
InventorsArnon Nagler, Israel Vlodavsky, Mark Pines, Shai Yarkoni
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for the treatment of renal fibrosis. This composition includes, as an active ingredient, a quinazolinone derivative such as halofurginone, which is shown herein to slow or prevent progression of renal fibrosis in vivo thereby mitigating or preventing end-stage renal failure.
Claims14
A composition for treating renal fibrosis, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carriers, said compound being a member of a group having the general formula:
- 11
- wherein:
- n=1-2
- R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;
- and
- R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.
A method for treating renal fibrosis in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a compound having the general formula:
- 12
- wherein:
- n=1-2
- R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and
- R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.
A method for preventing renal fibrosis from progressing to end-stage renal failure comprising administering to a subject in need thereof a therapeutically effective amount of compound in a pharmaceutically acceptable carrier, said compound being a member of a group having the general formula:
- 13
- wherein:
- n=1-2
- R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;
- and
- R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.
A method for preparing a pharmaceutical composition for treating renal fibrosis which comprises combining a compound being a member of the group having the general formula:
- 14
- wherein:
- n=1-2
- R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;
- and
- R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable carrier to form the composition for preparing a pharmaceutical composition for treating renal fibrosis.
Dependencies are inferred from the claim text.